Investors have turned back to U.S. healthcare names, allocating fresh capital to a sector that is beginning to benefit from a combination of improving profit trajectories, heightened dealmaking and valuations that many market participants view as compelling.
The shift comes as money flows and portfolio positioning broaden beyond the narrow group of technology companies closely tied to artificial intelligence that had dominated market gains earlier in the year. Over the last three months the S&P 500 healthcare index climbed 11.2% to reach a record high, outpacing the S&P 500’s 6% rise over the same period.
Investor interest is evident in fund flows: roughly 50 U.S.-listed healthcare funds attracted $2.44 billion in July, according to LSEG Lipper data, extending the nearly $1.5 billion that flowed in during June and reversing a three-month run of net withdrawals.
Drivers of the rebound
Analysts say the appeal is multifaceted. J.P. Morgan strategists led by Dubravko Lakos-Bujas put it succinctly: "Healthcare offers a rare combination of durable growth, technology-like profitability, attractive valuation and diversification benefits at a time when many investors remain heavily concentrated in the AI theme." A Bank of America survey showed global fund managers were net 32% "overweight" on healthcare stocks in July, up sharply from 14% in June.
Market participants point to an improving earnings picture as central to renewed optimism. LSEG’s Tajinder Dhillon forecasts double-digit earnings growth for S&P 500 healthcare companies beginning in the fourth quarter of 2026 and continuing through the end of 2027, which would represent a turnaround from the 16.7% earnings contraction the sector experienced in the second quarter of 2026.
"Sentiment around the healthcare sector had become overly negative, and recent earnings results and management commentary have helped alleviate some of these concerns," said James Harlow, director of research at Novare Capital Management. He cited examples such as drugmaker AbbVie topping second-quarter profit estimates, and health insurer UnitedHealth Group beating expectations and raising its 2026 forecast.
Dealmaking accelerates
Another factor augmenting investor interest has been a marked increase in merger and acquisition activity within the sector. Dealogic data show M&A value in healthcare has reached nearly $284 billion so far this year, approaching 2025’s total of $306 billion and surpassing every other year since 2021.
Recent media coverage noted that AstraZeneca and Bristol-Myers Squibb held talks about a potential merger that, if consummated, could create one of the largest pharmaceutical combinations in the world with a combined valuation approaching $400 billion. While talks do not guarantee a deal, the report underscores the heightened transaction environment that investors are watching closely.
Valuations and market context
Valuation metrics also figure into investor decisions. The healthcare sector was trading at roughly 18 times its 12-month forward earnings expectations, above its 20-year average of 15, while the S&P 500 as a whole traded near 20 times forward earnings. Some market participants view the sector as having been depressed for a prolonged period and therefore offering opportunities for reallocation.
"Healthcare valuations had been depressed for a long time and so there is some opportunity for investors," said Christian Peng, head of healthcare investment banking at Citizens Bank.
Still, a few strategists cautioned that rotations into beaten-down areas have not always persisted. Mark Hackett, chief market strategist for Nationwide, noted the unusual backdrop of the S&P 500 sitting at record highs even as investors move into previously forgotten corners of the market. He suggested that a sustained rebound will depend on follow-through with stronger earnings.
Political calendar and sector implications
Looking ahead, the upcoming November midterm elections are likely to keep healthcare in the political spotlight. The potential policy consequences vary depending on which party controls the House. If Democrats win the chamber, analysts say efforts could be revived to expand the Affordable Care Act, increase Medicaid funding and resist recent executive actions aimed at reducing coverage mandates. Such policy changes could favor health insurers with sizeable Medicaid and Affordable Care Act businesses and could lift hospital operators through higher insured patient volumes.
J.P. Morgan analysts noted that healthcare equipment and services companies have historically performed well during midterm years, though they do not anticipate a material change in healthcare policy this cycle. Some strategists see a divided government as a relative positive for the sector because it could reduce the probability of major, earnings-pressuring legislation.
"It’s a net positive for the healthcare sector because it means some of the threat of earnings-pressuring legislation could potentially go away," said Eric Parnell, chief market strategist at Great Valley Advisor Group.
Where the market impact shows up
The reallocation toward healthcare has implications beyond drugmakers and insurers. Financials have also seen gains as broader market participation expands, and hospital chains, equipment makers and service providers are among the subsectors investors are monitoring for earnings upside tied to both demographic trends and potential policy shifts.
For now, the combination of rising inflows, stronger near-term profit expectations and active transaction markets has shifted investor sentiment back toward a sector that had lagged earlier in the year. Whether that momentum continues will hinge on forthcoming earnings results, the trajectory of deal activity and the evolving political landscape through the midterms.